NCT03391804 is a Phase 2 clinical trial of ALLN-177 in Enteric Hyperoxaluria, sponsored by Allena Pharmaceuticals.

Who is sponsoring NCT03391804?

NCT03391804 is sponsored by Allena Pharmaceuticals.

What drugs are being tested in NCT03391804?

Interventions in NCT03391804: ALLN-177.

What condition does NCT03391804 study?

NCT03391804 studies Enteric Hyperoxaluria, Primary Hyperoxaluria, Hyperoxalemia.

Is NCT03391804 still recruiting?

NCT03391804 is currently completed. Last updated 30 December 2020.

Last reviewed 2020-12-30 · How we verify

NCT03391804

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia

Completed Phase 2 Last updated 30 December 2020

What this trial tests

Phase 2 trial testing ALLN-177 in Enteric Hyperoxaluria in 15 participants. Completed in 13 December 2019.

Timeline

17 July 2018

Primary endpoint
13 December 2019

13 December 2019

Quick facts

Lead sponsor	Allena Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	17 July 2018
Primary completion	13 December 2019
Estimated completion	13 December 2019
Sites	9 locations across United Kingdom, United States, Germany

Drugs / interventions tested

ALLN-177 — full drug profile →

Conditions studied

Enteric Hyperoxaluria — all drugs for Enteric Hyperoxaluria →
Primary Hyperoxaluria — all drugs for Primary Hyperoxaluria →
Hyperoxalemia — all drugs for Hyperoxalemia →

Sponsor

Allena Pharmaceuticals — full company profile →

Who can join

12 and older, any sex, with Enteric Hyperoxaluria or Primary Hyperoxaluria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate the efficacy and safety of ALLN-177 in reducing plasma and urinary oxalate levels in adult and pediatric patients with enteric hyperoxaluria and hyperoxalemia or primary hyperoxaluria

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Perspectives in primary hyperoxaluria - historical, current and future clinical interventions.
Shee K, Stoller ML. · · 2022 · cited 41× · PMID 34880452 · DOI 10.1038/s41585-021-00543-4
Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia.
Pfau A, Grujic D, Keddis MT, Kausz AT, et al · · 2021 · cited 9× · PMID 33416876 · DOI 10.1093/ndt/gfaa379
Navigating the Evolving Landscape of Primary Hyperoxaluria: Traditional Management Defied by the Rise of Novel Molecular Drugs.
Huang Y, Zhu W, Zhou J, Huang Q, et al · · 2024 · cited 1× · PMID 38785918 · DOI 10.3390/biom14050511

Verify or expand the search:

Other trials of ALLN-177

Trials testing the same drug.

NCT03456830 — Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria · Phase 3 · completed

Other recruiting trials for Enteric Hyperoxaluria

Currently open trials in the same condition.

NCT05124886 — Gut Kidney Axis in Enteric Hyperoxaluria · NA · recruiting

Other Allena Pharmaceuticals trials

Trials by the same sponsor.

NCT04987294 — Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease · Phase 2 · terminated
NCT05168683 — Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets · Phase 1 · completed
NCT04987242 — An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201) · Phase 2 · completed
NCT04829435 — Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase) · Phase 1 · completed
NCT04236219 — ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03391804 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Allena Pharmaceuticals
Last refreshed: 30 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03391804.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing